NCT04965064 2025-12-15
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
University of Rochester
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06764940 2025-11-28
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06374888 2024-04-19
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT02614794 2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2 Completed
NCT02000882 2022-02-07
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
Phase 2 Completed
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00570908 2014-09-18
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Baylor Breast Care Center
Phase 2 Terminated
NCT00967031 2013-01-18
Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases
UNICANCER
Phase 2 Completed
NCT00227656 2012-12-11
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00504660 2012-01-11
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
M.D. Anderson Cancer Center
Phase 2 Completed